Loading...
ABOUT2018-10-04T14:48:23+00:00

Our Company

Targepeutics, Inc. is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other dreaded diseases. Targepeutics has licensed a broad platform of anticancer technologies with the leading arm based on re-engineered Interleukin 13 that targets receptors overexpressed specifically on cancer cells. Targepeutics has also licensed technologies for the treatment, as well as the imaging and diagnosis of brain tumors.

Intratumoral TPI-013 in Solid Tumors Expressing IL13Rα2

  • Tumor targeting technology invented at Penn State Hershey Medical Center
  • Exclusively licensed to Targepeutics Inc
  • Precision molecular profile of tumor
    • Therapeutics
    • Diagnostics
    • Immunotherapy
  • Broadly applicable platform
  • Basket clinical trial design
  • Seamless clinical development

Our Unique Discovery

Our lead compound GB-13 is genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.

Targepeutics’ genesis was the decision of its founder, Waldemar Debinski not to pursue investment funding for his discovery that IL-13 could be developed into a cancer-targeting compound. While another company picked up licensing rights for this naturally occurring compound, Dr. Debinski decided to go back to work in his lab as he was scientifically unsatisfied with the compound’s remaining affinity to bind with normal cells. After substantial development, Dr. Debinski successfully mutated two new generations of IL-13 compounds that have very little affinity to bind with normal cells.Dr. Debinski’s completion of this development will allow Targepeutics to move its lead compound, GB-13, into Phase I clinical trials for high-grade glioma (brain cancer).

Technology License Agreement – Targepeutics’ entire technology portfolio has been exclusively licensed from the Pennsylvania State University, which owns all patent filings.

Management & Advisors

Silvan B. Lutkewitte, III
President and C.E.O

Sil started his career at Deliotte & Touche in audit and corporate finance positions. Since then, he has brought an entrepreneurial spirit to a number of start-ups in the early drug development space.  His experiences include executive level managerial and business development roles with companies developing cancer and inflammatory therapies and iron replacement therapies.  He has successfully negotiated license agreements with academic institutions, and out licensing agreements with two public biotech companies.  In addition, Sil has served on a number boards including Penn State/Hershey Medical Center Children’s Hospital and the Medical Center’s Cancer Institute.  Mr Lutkewitte is a founding member of Sidero Bioscience.

Darren Wolfe, PhD
CEO & Vice-Chairman of the Board of Directors

Dr Wolfe is a seasoned biotechnology start-up entrepreneur contributing expertise in biopharmaceutical development, clinical research, bioengineering, intellectual property, strategic planning and business administration.  Dr Wolfe is an inventor of several platform intellectual property portfolios.  Prior to joining Sidero, he founded and was President & CEO of PeriphaGen Holdings, a biotechnology company focused on the development of novel gene therapies targeting the human nervous system.  Previously, Dr Wolfe advanced to become President & CEO of Diamyd Incorporated and directed business development, preclinical, clinical, legal, and financial activities of the company.  Dr Wolfe has over 60 scientific publications on a variety of medical development areas and has been awarded numerous patents and federal grants.

Lynn W. Maines, Ph.D., M.B.A
Co-founder, Vice President, Business Development and Operations

Lynn served as a Fellow at Penn State’s Office of Technology Transfer evaluating medical technology for commercial application; has overseen entire formation of Targepeutics’ corporate structure from inception.

Waldemar Debinski, M.D., Ph.D.
Co-founder and Consulting Scientific Officer

Director of The Brain Tumor Center of Excellence, Wake Forest University; leading authority on receptor-specific chimeric proteins expressed by tumor cells and immunological aspects of cancer treatment; distinguished academic and scientific career at the National Institutes of Health and Clinical Research Institute of Montreal and Hotel-Dieu Hospital; author of nearly 200 scientific reports; received the Excellence in Basic Research Award in 2000 from the Society for Neuro-Oncology.

Gerard C. Smith, CFA
Financial Advisor

Managing Director of Equities, Public School Employees Retirement System; responsible for over $14 billion of internally managed equities, over 20 years public equity and venture capital experience.

Akiva Mintz, M.D.-Ph.D.
Vice President of Research and Development

Dr. Mintz has spent 10 years developing various cancer-targeted therapies and imaging tracers. He trained under the mentorship of Dr. Debisnki where he co-developed some novel anti-IL13Ra2 targeted therapies. Completed a clinical internship and a 2 year NIH-sponsored Molecular Imaging fellowship at the University of Pennsylvania with a focus on multimodality molecular imaging of cancer. Has also passed all three Chartered Financial Analyst exams.

Alfred W. Alberts, Ph.D.
Consultant

Alfred specializing in drug discovery and development. He retired in 1995 from Merck Research Laboratories where his most recent position was Vice President, Biochemistry and Director of Natural Product Drug Discovery.  While at Merck he directed programs in atherosclerosis, diabetes and obesity.  He was responsible for the discovery and development of lovastatin (Mevacor) and simvastatin (Zocor).    He is the recipient of a number of honors including the Pharmaceutical Manufacturers Association Discoverers Award, the “Inventor of the Year” award granted by the Intellectual Property Owners, Inc., the “Thomas Alva Edison” Award, the Merck Director’s Award and an honorary Doctor of Science from the University of Maryland.

With manufacturing of their first compound complete, Targepeutics’ path to clinical trials is clear. Coupled with their entire portfolio of compounds, Targepeutics’ future looks extraordinary.